Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, Share & Trends Analysis Report By Product Type (CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others), By Application Type (Hospital, Clinic, Research Center) Based On Region, And Segment Forecasts, 2022 - 2028

  • Report ID: BMRC 1074 | Number of pages: 200 | Published Date: Mar 2022

    Published | Category: Healthcare | Delivery Timeline: 48 hrs

COVID-19
To know the impact of COVID-19 On Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, Share & Trends Analysis Report By Product Type (CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others), By Application Type (Hospital, Clinic, Research Center) Based On Region, And Segment Forecasts, 2022 - 2028 Market

Request Now
Market Size Forecast Scenarios (Optimistic, Baseline and Pessimistic) 2021-2027

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market is valued at USD xx Billion in 2021 and is expected to reach USD xx Billion by 2028 with a CAGR of xx% over the forecast period.

The surge in the number of infectious diseases, favorable government initiatives for precautionary treatments, and the rapidly growing geriatric population are supporting the growth of the Severe Acute Respiratory Syndrome (SARS) Therapeutics market.

Coronavirus pandemic has gripped many corners of the global economy. As the pandemic Alters our economic life, it is important to track this development in real-time. We at Brandessence market research are conscious of the changing economic ground reality. All our new reports, and market forecast offer an in-depth analysis of the impact of the covid-19 pandemic. 

Scope of the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market:

Severe acute respiratory syndrome (SARS) is a contagious and fatal respiratory illness that first seemed in China in 2002. SARS normally begins with flu-like symptoms such as fever, chills, muscle aches, headache, and diarrhea. SARS is normally spread through droplets that enter the air when someone with the disease coughs or sneezes and it is spread mainly through close personal contact. Prevention of spread is extremely important for this highly infectious disease. Research is currently ongoing on the stage to develop an effective antiviral drug for SARS-CoV. Until then, people with SARS receive some supportive therapy and antibiotics to prevent this infection. For the treatment of SARS many therapies are proven to be effective and it including supporting breathing using a ventilator to deliver oxygen, antibiotics to treat bacteria that cause pneumonia, antiviral medicines, and high doses of steroids to reduce swelling in the lungs.

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Segmentation:-

The severe acute respiratory syndrome (SARS) therapeutics market is segmented on the basis of product type, application, and by region. Based on product type the severe acute respiratory syndrome (SARS) therapeutics market is segmented into CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, and others. Based on application, the market is divided into hospitals, clinics, and research centers.

By Product Type:

  • CEL-1000
  • D-3252
  • FDX-000
  • INO-4500
  • LCA-60
  • Others

By Application Type:

  • Hospital
  • Clinic
  • Research Center

The regions covered in this severe acute respiratory syndrome (SARS) Therapeutics market report are North America, Europe, Asia-Pacific and the Rest of the World. On the basis of country level, the market of severe acute respiratory syndrome (SARS) therapeutics market is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.

SARS Therapeutics Market

Severe Acute Respiratory Syndrome (SARS) Therapeutics Companies:

Key players of the severe acute respiratory syndrome (SARS) Therapeutics market are,

  • CEL-SCI Corporation
  • GeneCure LLC
  • Humabs BioMed SA
  • Inovio Pharmaceuticals Inc.
  • Nanotherapeutics, Inc.,
  • Novavax
  • Phelix Therapeutics
  • Protein Sciences Corporation
  • Others.

The surge in the number of infectious diseases, favorable government initiatives for precautionary treatments and the rapidly growing geriatric population is driving the growth of the severe acute respiratory syndrome (SARS) Therapeutics market.

The growth of severe acute respiratory syndrome (SARS) Therapeutics is primarily driven by some key factors such as a surge in a number of infectious diseases caused by a SARS-associated coronavirus, favorable government initiatives for precautionary treatments, and a rapidly growing geriatric population. During the period of SARS infection, there were around 8,098 reported cases of SARS and 774 deaths meaning that this virus killed about 1 in 10 people who were infected. According to WHO, on a global basis around 170,000 cases of coronavirus disease 2019 (COVID-19) caused by the novel coronavirus (SARS-CoV-2) have been detected with around 7,000 deaths in 150 countries.

SARS-related viruses are a newly emerged infectious disease in the 21st century that can be considered a serious threat to international health. To deal with these situations, various therapies are required in order to reduce vital diseases. Moreover, the increasing need for immunization, rising focus on reducing viral load, growing incidences of respiratory diseases, and prevalence of pneumonia are other driving factors supporting the growth of this market within the forecast period. However, regulatory compliance and culture condition requirements may hamper the growth of this market. Further research & development of rapid diagnostic tests and effective treatment will be urgently needed and this will offer lucrative opportunities for this market in near future.

North America is expected to dominate the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market

North America is expected to dominate the largest market share for severe acute respiratory syndrome (SARS) therapeutics due to well developed healthcare infrastructure, increasing government funding for the prevention of severe infectious diseases and significant improvements in clinical management. For instance; in the United States, the National Institutes of Health (NIH), healthcare companies, and collaborators are working on the development of vaccines and therapeutics for COVID-19. On 20th March 2020; around 5594 new cases and 49 new deaths in the United States have been reported. Asia pacific is emerge as the fastest-growing region in the severe acute respiratory syndrome (SARS) Therapeutics market owing to the technological advancements in healthcare systems such as RNA interference, DNA vaccines, and CRISPR technology, increasing infectious diseases, and rising standardized comprehensive program in Asian countries leading to the growth of this market. 

On Special Requirement severe acute respiratory syndrome (SARS) therapeutics market Report is also available for below Regions and Country:

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Sweden
  • Netherland
  • Turkey
  • Switzerland
  • Belgium
  • Rest of Europe

Asia-Pacific

  • South Korea
  • Japan
  • China
  • India
  • Australia
  • Philippines
  • Singapore
  • Malaysia
  • Thailand
  • Indonesia
  • Rest Of APAC

Latin America

  • Mexico
  • Colombia
  • Brazil
  • Argentina
  • Peru
  • Rest of South America

Middle East and Africa

  • Saudi Arabia
  • UAE
  • Egypt
  • South Africa
  • Rest Of MEA
Report Analysis Details
Historical data 2015 - 2020
Forecast Period 2021 - 2027
Market Size in 2020: USD XXX Million 
Base year considered 2020
Forecast Period CAGR %:

XX% 

Market Size Expected in 2027: USD XXX Million 
Tables, Charts & Figures: 175
Pages 200
(SARS) Therapeutics Companies: CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals Inc., Nanotherapeutics, Inc., Novavax, Phelix Therapeutics, Protein Sciences Corporation, Others.
Segments Covered By Product Type, By Application Type
Regional Analysis North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Reports:-

  • Global SARS Therapeutics Market report covers in-depth historical and forecast analysis.
  • Global SARS Therapeutics Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country levels.
  • Global SARS Therapeutics Market report helps to identify opportunities in the marketplace.
  • Global SARS Therapeutics Market report covers extensive analysis of emerging trends and competitive landscape.


Frequently Asked Questions (FAQ) :
Severe acute respiratory syndrome (SARS) is a contagious and fatal respiratory illness that first seemed in China in 2002. SARS normally begins with flu-like symptoms such as fever, chills, muscle aches, headache, and diarrhea.
CEL-SCI Corporation, GeneCure LLC, Humabs BioMed SA, Inovio Pharmaceuticals Inc., Nanotherapeutics, Inc., Novavax, Phelix Therapeutics, Protein Sciences Corporation, Others.
North America is expected to dominate the Severe Acute Respiratory Syndrome (SARS) Therapeutics Market
Surge in number of infectious diseases, favorable government initiatives for precautionary treatments and rapidly growing geriatric population is driving the growth of the severe acute respiratory syndrome (SARS) therapeutics market.



Interested in this report?

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, Share, and Industry Analysis

report cover

Severe Acute Respiratory Syndrome (SARS) Therapeutics Market Size, Share & Trends Analysis Report By Product Type (CEL-1000, D-3252, FDX-000, INO-4500, LCA-60, Others), By Application Type (Hospital, Clinic, Research Center) Based On Region, And Segment Forecasts, 2022 - 2028

Note: For delivery of sample pages you must have a Domain Specific Email ID, normally your business email address complies. Generic Email IDs such as AOL, Hotmail, Yahoo, Gmail, MSNetc. are not accepted.
Brandessence market research actively tracks, monitors, and analyses key industry trends in real-time via B2B surveys in 60 + countries and territories.

    Pricing


Looking for Regional Reports?